Celator Pharmaceuticals, Inc.
303B College Road East
Princeton
New Jersey
08540
United States
Tel: 609-243-0123
Fax: 609-243-0202
Website: http://www.celatorpharma.com/
Email: info@celatorpharma.com
170 articles about Celator Pharmaceuticals, Inc.
-
Merrimack Divests Early Stage Asset for $2.25 Million; Provides Strategy Update
4/2/2020
Merrimack Pharmaceuticals, Inc. announced receipt of $2.25 million in connection with the closing of a transaction in which the Company sold certain assets related to its preclinical nanoliposome programs to Celator Pharmaceuticals, Inc.
-
Former Celator CPA Connived With Two Friends, Father on Insider-Trading Scheme
9/1/2017
-
FDA Berates Celator Pharma for Pushing Unapproved Leukemia Drug to Doctors
9/8/2016
-
Jazz Pharma Announces Results Of Tender Offer To Purchase All Of The Outstanding Shares Of Common Stock Of Celator Pharma
7/12/2016
-
Jazz Pharma Announces Expiration Of HSR Waiting Period For Proposed Celator Pharma Acquisition
6/27/2016
-
Celator Pharma Announces Positive Results In Patients With FLT3 Mutation From The Phase 3 Trial In High-Risk Acute Myeloid Leukemia
6/15/2016
-
ASCO2016: Celator Pharma Presented Phase 3 Trial Results In Patients With High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS (CPX-351) Significantly Improved Overall Survival
6/6/2016
-
2 Stocks Billionaires Who Made a Killing Off of Celator Pharma are Buying
6/3/2016
-
Jazz Pharma Pays $1.5 Billion for Celator Pharma to Gain a Promising Leukemia Drug
6/1/2016
-
Celator Pharma Cancels Analyst And Investor Meeting And Postpones Annual Meeting Of Stockholders
6/1/2016
-
Celator Pharma Announces Upcoming Phase 3 Data Presentations At ASCO And European Hematology Association
5/20/2016
-
Celator Pharma Jumps on Breakthrough Therapy Win for Lead Cancer Drug
5/19/2016
-
Celator Pharma Announces First Quarter 2016 Financial Results And Business Update
5/11/2016
-
Celator Pharma To Report First Quarter 2016 Financial Results On May 10, 2016
5/4/2016
-
Celator Pharma Announces Positive Results Demonstrating Reduced Healthcare Resource Use With VYXEOSTM Compared To Standard Treatment For Acute Myeloid Leukemia (AML)
4/25/2016
-
Celator Pharma To Present Phase 3 Data At 2016 ASCO Annual Meeting
4/21/2016
-
Celator Pharma Reports On Previously Suspended Investigator-Initiated Clinical Study
4/19/2016
-
Celator Pharma Announces Positive Data For VYXEOS In FLT3-ITD Mutated Acute Myeloid Leukemia (AML) Cells Derived From Patients With Newly Diagnosed AML
4/18/2016
-
Celator Pharma Announces New Data For VYXEOS In FLT3-ITD Mutated AML Cells Derived From Patients With Newly Diagnosed AML To Be Presented At The AACR Annual Meeting
4/18/2016
-
3 Life Sciences Companies Heading Into Orbit or On the Launching Pad
4/13/2016